Intel stock spikes after report of possible US government stake
On Monday, H.C. Wainwright initiated coverage on Ionis Pharmaceuticals (NASDAQ:IONS) with a positive outlook, assigning a Buy rating and a price target of $45.00 per share. The firm’s analyst highlighted Ionis’ robust pipeline of antisense oligonucleotide therapies and its focus on RNA-targeted therapeutics for a variety of diseases, including those related to cardiology and neurology. Currently trading at $27.09, the stock has faced significant pressure, declining over 10% in the past week and trading near its 52-week low of $26.88. InvestingPro data reveals analyst targets ranging from $37 to $78, suggesting potential upside despite recent weakness.
Ionis Pharmaceuticals, a commercial-stage biotechnology company with a market capitalization of $4.3 billion, is currently preparing for the launch of two significant products. Tryngolza (olezarsen) is anticipated to lower triglycerides, and Wainua (eplontersen) is being developed to treat transthyretin-mediated amyloidosis (ATTR). The analyst expressed a high level of confidence in Tryngolza’s potential, especially with upcoming Phase 3 readouts in the second half of 2025 for severe hypertriglyceridemia (sHTG). Success in these trials could lead to approval in sHTG, granting Ionis full U.S. rights and substantial rights outside the U.S. to a drug with a total addressable market of approximately 2.3 million patients in the U.S. alone. According to InvestingPro, the company maintains strong liquidity with a current ratio of 8.47, providing ample resources for its development programs.
Furthermore, the analyst anticipates the approval of donidalorsen for hereditary angioedema (HAE) by the PDUFA date of August 21, 2025, given the drug’s data appears comparable to the standard-of-care, with the added benefit of less-frequent dosing. The firm believes the market has yet to fully recognize the potential for differentiation that donidalorsen offers compared to existing treatments. With the next earnings report due on April 30, investors seeking deeper insights can access comprehensive analysis through InvestingPro’s detailed research reports, which cover key financial metrics and growth prospects for over 1,400 US stocks.
The report also points out that Ionis is well-positioned ahead of these 2025 catalysts, with impactful events expected in 2026 and a strong cash position to support its operations. While the company operates with a moderate level of debt, its healthy liquidity position provides financial flexibility. The analyst’s confidence in the upcoming product launches and pivotal data readouts underpins the Buy rating and the $45.00 price target for Ionis shares.
In other recent news, Ionis Pharmaceuticals has reported several significant developments. The company received approval from the European Union for its treatment WAINZUA, aimed at hereditary transthyretin-mediated amyloidosis, following successful trial results. Ionis has also announced a licensing agreement with Sobi to commercialize olezarsen, branded as TRYNGOLZA™, outside the U.S., following its FDA approval for familial chylomicronemia syndrome (FCS). Additionally, Ionis plans to expand olezarsen’s indication to treat severe hypertriglyceridemia (sHTG), with Phase 3 data expected in 2025.
Oppenheimer has maintained an Outperform rating on Ionis, citing the company’s strategic partnership with Ono Pharmaceuticals to develop sapablursen for polycythemia vera, which strengthens Ionis’s market position. UBS also kept a Neutral rating with a $45 price target, following discussions with Ionis’s management about their focus on TRYNGOLZA. Meanwhile, Redburn-Atlantic initiated coverage of Ionis with a Neutral rating and a $39 price target, noting the potential of the drug Wainua for ATTR-CM treatment but indicating a need for more data.
These developments highlight Ionis’s ongoing efforts in drug development and strategic partnerships. The company’s focus on RNA-targeted therapies is evident in its expanding pipeline and collaborations aimed at addressing rare and serious diseases. Investors and analysts are closely monitoring these advancements to assess Ionis’s growth potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.